Protalix BioTherapeutics Inc $4.13

down -0.04


24/4/2014 06:40 PM  |  AMEX : PLX  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get PLX Trend Analysis - it has underperformed the S&P 500 by 46%

Partner Headlines

  1. Protalix Offers Update on Health Canada Evaluation, Says Manufacturing ...

    Benzinga
  2. Protalix Reports Oral GCD Well Toleratead, Active Enzyme Detected in Blood

    Benzinga
  3. Protalix BioTherapeutics Announces Proposed $60M Offering of Convertible ...

    Benzinga
  4. Protalix Says New Clinical Data on ELELYSO Will Be Presented at WORLD Symposium

    Benzinga
  5. Benzinga's M&A Chatter for Tuesday February 5, 2013

    Benzinga
  6. Mid-Afternoon Market Update: Markets Edge Toward Record Highs, Arch Coal ...

    Benzinga
  7. Mid-Day Market Update: Markets Rally Further, Clean Harbors Drops on CFO ...

    Benzinga
  8. Protalix Says Reviewing Partnering, Other Alternatives

    Benzinga
  9. Protalix BioTherapeutics Signs Clinical Development Agreement With Pfizer ...

    Benzinga
  10. Protalix BioTherapeutics Inc Reports Operating Results (10-Q)

    GuruFocus
  11. Protalix BioTherapeutics Receives FDA IND Clearance to Initiate a Phase ...

    Benzinga
  12. Protalix BioTherapeutics Inc Reports Operating Results (10-Q)

    GuruFocus
  13. Benzinga's Downgrade Summary for June 25, 2012

    Benzinga
  14. Ryder System, Associated Estates Realty Corporation Among Stocks Down on ...

    FoxBusiness
  15. Ryder System, Protalix BioTherapeutics Gapping Down Friday

    FoxBusiness
  16. Protalix BioTherapeutics (PLX) Gains 18% After FDA Approval

    MarketIntelligenceCenter
  17. Protalix BioTherapeutics Inc Reports Operating Results (10-K)

    GuruFocus
  18. Notable Call Options Activity in Protalix BioTherapeutics

    Benzinga
  19. Protalix BioTherapeutics Announces the Pricing of Public Offering of Common ...

    Benzinga
  20. Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock; ...

    Benzinga
  21. FDA Delays Protalix's Drug Decision; Investors Feel Sick

    Benzinga
Trading Center